10 Must-Buy Penny Stocks to Invest In

2. Precigen, Inc. (NASDAQ:PGEN)

Year-To-Date Returns: 317.59%

Share Price: $4.51

Number of Hedge Fund Holders: 12

Precigen, Inc. (NASDAQ:PGEN) is one of the must-buy penny stocks to invest in. On August 19, Cantor Fitzgerald reaffirmed its “Overweight” rating on Precigen stock. The firm expressed growing confidence in Precigen’s upcoming launch of Papzimeos, the company’s newly approved product, following recent discussions with the company. Papzimeos received full FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), marking a major milestone for Precigen. Precigen set the wholesale acquisition cost for a full treatment cycle of the drug at $460,000.

The analysts’ thesis highlights Papzimeos as a significant revenue opportunity due to its unique position as the only FDA-approved RRP treatment and the company’s strategic preparations for its commercial launch. As such, Cantor Fitzgerald updated its financial model, estimating Precigen’s equity value at approximately $1.7-1.8 billion, which is about 3.3 times the projected peak sales for the company’s products, based on a discounted cash flow analysis.

Precigen, Inc. (NASDAQ:PGEN) is a biotech firm focused on gene and cell therapies for cancer, autoimmune conditions, and rare diseases. Using synthetic biology, its pipeline features innovative platforms—UltraCAR-T, ActoBiotics, and AdenoVerse—aimed at delivering precise, long-lasting, and cost-effective treatments.